Erschienen in:
04.01.2021 | ASO Author Reflections
ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve “Precision Onco-Surgery” in Resectable Colorectal Liver Metastases
verfasst von:
Shin Kobayashi, MD, PhD, Yoshiaki Nakamura, MD, PhD, Shinichiro Takahashi, MD, PhD, Hiroya Taniguchi, MD, PhD, Takayuki Yoshino, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2021
Einloggen, um Zugang zu erhalten
Excerpt
Numerous studies have proposed risk-scoring systems after hepatectomy for resectable colorectal liver metastases (CRLM) to guide perioperative treatment. Recent developments of precision oncology have demonstrated that molecular markers such as
RAS,
BRAF V600E,
PIK3CA,
SMAD4, and
TP53 predict poor prognosis.
1,
2 However, since all of them were analyzed by tissue-based polymerase chain reaction or next-generation sequencing, it was not possible to timely incorporate the information regarding genomic alterations into guiding perioperative treatment at time of diagnosis for CRLM. …